SXI Life Sciences
6.905,90
PKT
+48,39
PKT
+0,71
%
Werbung
Analysen zu SXI Life Sciences-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 21.06.05 | Novartis buy | Jyske Bank | |
| 17.06.05 | Novartis reduce | UBS | |
| 16.06.05 | Novartis neutral | Robert W. Baird | |
| 16.06.05 | Novartis | Weberbank | |
| 10.06.05 | Novartis halten | Fuchsbriefe | |
| 09.06.05 | BB Biotech | Kayenburg | |
| 08.06.05 | Novartis neutral | HypoVereinsbank | |
| 07.06.05 | Novartis neutral | Bank Sarasin & Cie | |
| 06.06.05 | Sonova | Die Actien-Börse | |
| 06.06.05 | Novartis buy | Merrill Lynch | |
| 03.06.05 | Novartis | Der Aktionärsbrief | |
| 03.06.05 | Novartis neutral | Bank Sarasin & Cie | |
| 02.06.05 | Novartis above average | Caris & Company | |
| 01.06.05 | Novartis Above Average | Caris & Company | |
| 30.05.05 | Novartis buy | Jyske Bank | |
| 23.05.05 | BB Biotech Kaufen | Geldbrief | |
| 26.05.05 | BB Biotech Kaufen | Geldbrief | |
| 26.05.05 | Novartis | JRC | |
| 23.05.05 | Novartis | JRC | |
| 18.05.05 | Roche Overweight | JP Morgan | |
| 18.05.05 | Roche Buy | Sarasin Research | |
| 18.05.05 | BB Biotech Kaufen | Hamburger Sparkasse | |
| 13.05.05 | Roche Outperform | Goldman Sachs | |
| 10.05.05 | Novartis Buy | Smith Barney Citigroup | |
| 04.05.05 | Roche Buy | Helvea | |
| 03.05.05 | Lonza Buy | Helvea | |
| 02.05.05 | Lonza Reduce | Sarasin Research | |
| 29.04.05 | Novartis Sector Perform | Vontobel | |
| 27.04.05 | Roche Overweight | JP Morgan | |
| 29.04.05 | Roche Sector Outperform | Vontobel | |
| 27.04.05 | Roche Outperform | Goldman Sachs | |
| 27.04.05 | Roche Kaufen | Hamburger Sparkasse | |
| 27.04.05 | Roche Buy | Helvea | |
| 26.04.05 | Straumann Outperform | Goldman Sachs | |
| 26.04.05 | Novartis Kaufen | Hamburger Sparkasse | |
| 25.04.05 | Straumann Sector Perform | Vontobel | |
| 22.04.05 | Novartis Hold | SEB | |
| 22.04.05 | Novartis Outperform | Goldman Sachs | |
| 22.04.05 | Novartis Overweight | Lehman Brothers | |
| 27.04.05 | Novartis Kaufen | NATIONAL-BANK |